Mobile apps are a fast paced technology that require ongoing iterations. At mySugr, we’ve learnt this first hand. A small change in something as “banal” as our welcome email can reverberate in unexpected ways throughout our 1.5 million user base. For better or worse, this means technology like ours doesn’t translate well into randomized clinical trials, the gold standard of prospective trials. By the time the publication date rolls around, we’re likely to be an entirely different animal.
A diabetes care program drives real world resultsTogether with ProSciento, we looked into the impact of the mySugr Bundle among our users. The mySugr Bundle is a subscription kit containing unlimited test strips, automatic supply refills, personalized coaching, and more. It is available to patients directly (out of pocket) and through health insurers and provider systems in Germany and the United States. Learn more about our digital population health management solution here. We looked into how people interact with the app just after registering, in the two months prior to receiving the mySugr Bundle and the two months after the bundle has arrived. We included data from people who measured their blood glucose levels on average three or more times per day during each period. Given the strict time frames and test frequency requirements for inclusion, and the recent launch of the mySugr Bundle in the U.S. market, the result was a pool of 52 participants with type 1, type 2, or latent autoimmune diabetes (LADA). The results are very encouraging. The population was already doing well and their diabetes management improved further:
- On average, participants’ blood glucose levels dropped from 154±55 mg/dl to 138±50 mg/dl
- Translated into HbA1c (by calculating the “estimated A1c”), this shows a mean drop from 6.7% to 6.3%
- This drop of 0.4% in an already “well controlled population” exceeds the 0.3% threshold for a therapy, device or medication to be seen as relevant
As lovable as NetflixThe mySugr Bundle was initially designed for people with type 1 diabetes, but over time we have seen strong uptake by the type 2 population. Members of this latter group who use the mySugr Bundle were analysed in a separate study, also presented at the 2018 Diabetes Technology Meeting, based on the results of a Net Promoter Score survey. The key question we asked through the Net Promoter Score (NPS) survey was; “How likely are you to recommend mySugr Bundle to a friend?” NPS is a tool that, using social mechanics, puts the question of love in context. Even if a user is “satisfied,” that doesn’t mean he or she would recommended it to a close friend. It’s a commonly used tool that can lead to deeper questions about why people love the product, as well as what needs to be worked on. As the score was calculated, we were surprised to see an NPS of nearly 70; on par with the likes of Netflix and Apple. Around 86% of respondents also reported being happy with the service they received through the remote certified diabetes educator (CDE) coaching. [caption id="attachment_12577" width="684"]
Virtual diabetes care can produce real world outcomesThere was a lot to celebrate in the two posters, including the fact that mySugr’s digital health solution can make a clinically relevant impact in diabetes management. By looking at real world evidence, we showed tangible results from our virtual diabetes care. All of this was achieved by engaging a patient community that can spread the gospel of what brought them there. We’ll keep you posted on the future learnings in this field, and look forward to writing our next update!
The mySugr website does not provide medical or legal advice. mySugr blog articles are not scientific articles, but intended for informational purposes only.
Medical or nutritional information on the mySugr website is not intended to replace professional medical advice, diagnosis or treatment. Always consult a physician or health care provider with any questions you may have regarding a medical condition.